Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Infertility 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 42Cytarabine 25fludarabine phosphate 24Dexamethasone 23Methotrexate 22fludarabine 21Peripheral Blood Stem Cell Transplantation 21Vincristine 16Filgrastim 16venetoclax 14Etoposide 13Rituximab 12Mycophenolic Acid 12Whole-Body Irradiation 11Cyclosporine 10Clofarabine 10Calcium Dobesilate 10blinatumomab 9Tacrolimus 9pegaspargase 8Busulfan 8Bortezomib 8Alemtuzumab 8Mitoxantrone 7Melphalan 7Leucovorin 7Immunotherapy, Adoptive 7nilotinib 6Mesna 6Mercaptopurine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Sitagliptin Phosphate × Clear all
NCT05895201 2024-04-29

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Indiana University

Phase 1/2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡